Message From Wall Street: Cap Those Price Increases
This article was originally published in RPM Report
With the Democrats in control of Congress and high drug prices still making headlines, some Wall Street analysts are suggesting a proactive, and surprising, response from Big Pharma: voluntary price caps.
You may also be interested in...
Why Payers Are Making Life Tougher for Oncology Marketers, and How Marketers Must Adapt.
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
The pharmaceutical industry has a lot riding on the mid-term elections: the Democrats only need to take back one chamber of Congress to do damage on Wall Street.